Not medical advice. Ipamorelin is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Ipamorelin is a growth-hormone secretagogue studied for pituitary signalling and pulse-like GH release patterns in animals -distinct from exogenous GH itself.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Ipamorelin, first selective growth hormone secretagogue with GHRH-like GH specificity and no significant ACTH, cortisol, or prolactin stimulation.
Peer-reviewed literature typically discusses Ipamorelin in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 100–300 mcg subcutaneously · 1–3 times daily, typically pre-sleep · Terminal t½ ≈ 2 h; clearance 0.078 L/h/kg; Vd = 0.22 L/kg; Tmax (GH peak) ≈ 40 min; SC bioavailability ~95%; intranasal bioavailability ~20%; 60–80% recovered as intact peptide in urine/bile indicating moderate metabolic resistance (Gobburu et al., Pharmaceutical Research, 1999).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the ghrelin/growth-hormone-secretagogue receptor (GHSR), prompting the pituitary to release growth hormone. It is one of the most selective GH secretagogues studied and is supplied as a lyophilised research-grade powder for laboratory use only.
In research models ipamorelin stimulates a clean, pulse-like release of growth hormone from the pituitary by acting on the GHSR receptor — without the cortisol, ACTH or prolactin spikes seen with GHRP-2/GHRP-6. These are findings in cell and animal models; no human therapeutic effect is implied.
In the research literature ipamorelin is used as a tool compound to study the growth-hormone axis, GH/IGF-1 signalling, body-composition and recovery endpoints, often alongside a GHRH analogue such as CJC-1295. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use.
In published animal studies ipamorelin has been well tolerated with a notably selective profile (minimal cortisol/prolactin effect), but there are no controlled human safety trials, so human safety is not established. It is a research compound, not a medicine; New-U makes no human-use claims and supplies it for laboratory research only.
No. Ipamorelin is an investigational research peptide and is not approved by the FDA, EMA, or any other regulator for human therapeutic use. It is sold strictly for preclinical and in-vitro research.
GHRP-2 and GHRP-6 both activate the ghrelin receptor but also trigger noticeable increases in cortisol, ACTH, and prolactin at GH-releasing doses. Ipamorelin does not - even at doses hundreds of times above its GH-releasing threshold, those secondary pituitary effects remain flat.
Yes - this is the most common research stack in the GHRP family. Ipamorelin activates the ghrelin receptor while CJC-1295 activates the GHRH receptor, and the two mechanisms produce supra-additive GH release. The pairing is used to mimic physiologic pulsatile GH secretion.
Ipamorelin produces far weaker orexigenic effects than GHRP-6 in comparative studies. Its ghrelin-receptor selectivity is tuned toward somatotroph activation rather than hypothalamic appetite signalling, so appetite stimulation is typically minimal in research protocols.
Keep the lyophilised powder frozen at −20 °C until reconstitution. After mixing with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Ipamorelin is stable in solution within the normal peptide-handling window.
Research-grade ipamorelin is priced per vial and sold by New-U in sealed 10-vial research packs, with the per-mg cost falling on larger vials. Every pack is >99% HPLC-verified with a batch-linked Certificate of Analysis. See the New-U ipamorelin page for current per-vial pricing; supplied for laboratory research use only.
The most-studied GH-axis pairing combines ipamorelin (a ghrelin-receptor agonist) with CJC-1295 (a GHRH analogue). Monthly research cost depends on the amounts and frequency a protocol uses for each vial; because both are sold in 10-vial packs at per-vial pricing, larger vials lower the per-mg cost of the pairing. New-U publishes per-vial pricing on each product page - this is research-supply cost context, not a human-use dosing or cost recommendation.
Published research protocols describe microgram-range subcutaneous amounts, often once to a few times daily, sometimes timed to the natural nocturnal GH pulse. New-U publishes this as descriptive research context only - it is not a dosing instruction, and ipamorelin is supplied strictly for laboratory research, not human use.
Ipamorelin is studied for selective growth-hormone release and downstream GH/IGF-1-axis endpoints (body composition, recovery, sleep) without the cortisol, prolactin or strong appetite signals seen with GHRP-6. These are research findings; New-U makes no therapeutic claims and sells ipamorelin for research use only.
All three raise growth hormone but through different receptors/scaffolds: ipamorelin is a clean, selective ghrelin-receptor (GHSR) agonist; sermorelin is a GHRH analogue acting upstream on the pituitary; hexarelin is a more potent GHRP-6-type GHSR agonist with added CD36 cardiac activity but more cortisol/prolactin. See our Ipamorelin vs Sermorelin and Hexarelin vs Ipamorelin research comparisons for the full breakdown.
For growth-hormone-secretagogue peptides such as ipamorelin, the published research is informative: these compounds work by transiently stimulating the body's own GH pulses rather than replacing a hormone, so when administration stops the endogenous GH/IGF-1 axis returns toward its untreated baseline without the prolonged suppression seen after exogenous HGH. Effects observed during a study taper off as the short-acting peptide clears. These are research-model observations — ipamorelin is supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Ipamorelin.
Primary literature and registries for Ipamorelin, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: NNC 26-0161, Ipamorelin Acetate, IPA, Selective GH Secretagogue